Saurabh Sharma

This study establishes patient-derived melanoma organoids (PDMOs) that retain tumor-immune heterogeneity and show context-dependent responses to immune checkpoint blockade.

This paper introduces a BBB-penetrating nanoconjugate for glioblastoma treatment that modulates the PD-1/PD-L1 axis without antibodies, showing improved brain accumulation and immune activation in vitro and in vivo.

This paper uses single-cell Raman spectroscopy and machine learning to predict therapeutic response in melanoma, achieving >96% accuracy in cell line classification and 91% accuracy in patient drug resistance inference.

This paper develops a 3D GBM model with pericytes to study TMZ resistance, finding that pericytes increase TMZ resistance in GBM spheroids by upregulating CCL5.

This study identifies six myeloid cell clusters in melanoma using scRNA-seq, finding that M_C1 subtype frequency predicts survival and immunotherapy response.